International Journal of Hematology-Oncology and Stem Cell Research 2017. 11(2):114-120.

Aberrant Methylation-Mediated Suppression of APAF1 in Myelodysplastic Syndrome
Farhad Zaker, Nahid Nasiri, Naser Amirizadeh, Seyed Mohsen Razavi, Marjan Yaghmaie, Ladan Teimoori-Toolabi, Ali Maleki, Masoumeh Bakhshayesh

Abstract


Background: Myelodysplastic syndromes (MDSs) include a diverse group of clonal bone marrow disorders characterized by ineffective hematopoiesis and pancytopenia.It was found that down regulation of APAF1, a putative tumor suppressor gene (TSG),leads to resistance to chemotherapy and disease development in some cancers. In this study, we investigated the relation of APAF1 methylation status with its expression and clinicopathological factors in myelodysplastic syndrome (MDS) patients. Materials and Methods: Methylation Sensitive-High Resolution Melting Curve Analysis (MS-HRM) was employed in studying the methylation of CpG islands in the APAF1promoter region in MDS. Gene expression was analyzed by using real time RT-PCR.
Results: 42.6% of patient samples were methylated in promoter region of APAF1 analyzed, while methylation of the genewas not seen in controls (P<0.05). Methylation of APAF1 was significantly associated with the suppression of its mRNA expression (P=0.00). The methylation status of APAF1in advanced-stage MDS patients (80%) was significantly higher than that of the early-stage MDS patients (28.2%) (P=0.001). The difference in frequency of hypermethylated APAF1 gene was significant between good (37.5%) and poor (85.71%) cytogenetic risk groups (P=0.043). In addition, a higher frequency of APAF1 hypermethylation was observed in higher-risk MDS group (69.2%) compared to lower-risk MDS group (34.14%) (P=0.026).
Conclusion: Our study indicated that APAF1hypermethylation in MDS was associated to high-risk disease classified according to the IPSS, WHO and cytogenetic risk.


Keywords


HRM; Methylation; Myelodysplastic syndrome; APAF1

Full Text:

Untitled PDF

References


Visconte V, Tiu RV, Rogers HJ. Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease. Blood Res. 2014;49(4):216–227.

Bejar R, Steensma DP. Recent developments in myelodysplastic syndromes. Blood. 2014;124(18):2793–803.

Baylin SB . DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol. 2005;Suppl 1:S4–11.

Rice KL, Hormaeche I, Licht JD. Epigenetic regulation of normal and malignant hematopoiesis. Oncogene. 2007;26(47):6697–714.

Jiang Y, Dunbar A, Gondek LP, et al . Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood.2009; 113(6):1315–25.

Li C, Wang L, Su J, et al.mRNA expression and hypermethylation of tumor suppressor genes apoptosis protease activating factor-1 and death-associated protein kinase in oral squamous cell carcinoma. Oncol Lett. 2013;6:280–6.

Christoph F, Hinz S, Kempkensteffen C,et al. mRNA expression profiles of methylated APAF-1 and DAPK-1 tumor suppressor genes uncover clear cell renal cell carcinomas with aggressive phenotype. J Urol. 2007;178(6):2655–9.

Bratton SB, Salvesen GS. Regulation of the Apaf-1-caspase-9 apoptosome. J Cell Sci. 2010;123(19):3209–14.

Yuan S, Yu X, Topf M, et al. Structure of an apoptosome-procaspase-9 CARD complex. Structure. 2010;18(5):571–83.

Riedl SJ, Salvesen GS. The apoptosome: signalling platform of cell death. Nat Rev Mol Cell Biol. 2007; 8(5):405–13.

Robles AI, Bemmels NA, Foraker AB, et al. APAF-1 is a transcriptional target of p53 in DNA damage-induced apoptosis. Cancer Res. 2001;61(18):6660–4.

Soengas MS, Alarcón RM, Yoshida H, et al . Apaf-1 and Caspase-9 in p53-Dependent Apoptosis and Tumor Inhibition. Science. 1999; 284(5411):156–9.

Campioni M, Santini D, Tonini G, et al . Role of Apaf-1, a key regulator of apoptosis, in melanoma progression and chemoresistance. Exp Dermatol. 2005;14(11):811–8.

Fujimoto A, Takeuchi H, Taback B, et al . Allelic imbalance of 12q22-23 associated with APAF-1 locus correlates with poor disease outcome in cutaneous melanoma. Cancer Res. 2004;64(6):2245–50.

Soengas MS, Capodieci P, Polsky D, et al . Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature. 2001; 409(6817):207–11.

Yaghmaie M, Gerayeli N, Ghaffari SH, et al . Some Specific Chromosomal Aberrations of Hematologic Malignancies in 80 Iranian Population. IJHOSCR. 2009;3(3):29–33.

Kerbauy DB, Deeg HJ . Apoptosis and anti-apoptotic mechanisms in the progression of MDS. Exp Hematol. 2007;35(11):1739–46.

Diamantidis M, Dimoudis S, Klonizakis P, et al . The role of apoptosis and current therapeutic challenges in myelodysplastic syndromes. Hippokratia. 2007;11(4):178–82.

Momparler RL. Cancer epigenetics. Oncogene. 2003;22(42):6479–83.

Furukawa Y, Sutheesophon K, Wada T, et al. Methylation Silencing of theApaf-1Gene in Acute Leukemia. Mol Cancer ReS. 2005;3(6):325–34.

Benites BD, Traina F, Duarte ADSS, et al. Increased expression ofAPAF-1in low-risk myelodysplastic syndrome: a possible role in the pathophysiology of myelodysplasia. Eur J Haematol. 2010;84(6):525–30.

Baylin SB, Jones PA . A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011;11(10):726–34.

Jones PA, Baylin SB . The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3(6):415–28.

Shen L, Kantarjian H, Guo Y, et al . DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol. 2010;28(4):605–13.

Triantafyllidis I, Ciobanu A, Stanca O, et al .Prognostic Factors in Myelodysplastic Syndromes. Maedica (Buchar). 2012;7(4):295–302.

Souza DCD, Fernandez CDS, Camargo A, et al . Cytogenetic as an Important Tool for Diagnosis and Prognosis for Patients with Hypocellular Primary Myelodysplastic Syndrome. Biomed Res Int. 2014;1–10.

Kalaycio M, Rybicki L, Pohlman B, et al . Elevated lactate dehydrogenase is an adverse predictor of outcome in HLA-matched sibling bone marrow transplant for acute myelogenous leukemia. Bone Marrow Transplant. 2007;40(8):753–8.

Palumbo A, Avet-Loiseau H, Oliva S, et al . Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863–9.

Wimazal F, Sperr WR, Kundi M, et al . Prognostic significance of serial determinations of lactate dehydrogenase (LDH) in the follow-up of patients with myelodysplastic syndromes. Ann Oncol. 2008;19(5):970–6.

Ahmad ST, Arjumand W, Seth A,et al . Methylation of the APAF-1 and DAPK-1 promoter region correlates with progression of renal cell carcinoma in North Indian population. Tumour Biol. 2012;33(2):395–402.

Fu WN, Bertoni F, Kelsey SM, et al . Role of DNA methylation in the suppression of Apaf-1 protein in human leukaemia. Oncogene. 2003;22:451–5.


Refbacks

  • There are currently no refbacks.


Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.